EMA announced on 31 May 2012 that it had released a revised guideline for public consultation describing how pharmaceutical companies should address the quality aspects of biosimilar medicines.
EMA revised guideline on quality of biosimilar medicines open for comments
Home/Guidelines
|
Posted 08/06/2012
0
Post your comment
The guideline is intended to update the previous guidance from 2006 and explains the requirements for the manufacture and comparability testing for biological medicines claiming to be similar to another medicine already on the market, i.e. biosimilars.
The revised guideline was adopted by the Agency’s Committee for Medicinal Products for Human Use in May 2012 and is open for consultation until the end of November 2012.
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
Effective date: 31 May 2011
End of consultation: 30 Nov 2012
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf
Comments on the revised guideline can be sent to bwp.biosimilar.revision@ema.europa.eu using the form for submission of comments at the EMA website.
Related article
Source: EMA
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Related content
Regulatory update for post-registration of biological products in Brazil
Home/Guidelines Posted 29/10/2024
FDA interchangeable biosimilars guidance update on revised approach to switching studies
Home/Guidelines Posted 23/07/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment